Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 29, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
- On the same day, Hohl sold 3,250 shares of common stock at a weighted average price of $16.9737 per share, with individual sales prices ranging from $16.56 to $17.41.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following the reported transactions, Hohl directly owns 222,120 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, which doesn't inherently convey positive or negative sentiment. The transactions are pre-planned.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 2022-08-02 | One-fourth of the stock options vested. |
| 2023-06-26 | Rule 10b5-1 trading plan adopted by Benjamin Hohl. |
| 2024-04-29 | Benjamin Hohl exercised stock options and sold shares. |
| 2031-08-02 | Expiration date of the stock options. |
| 2024-05-01 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.